179 related articles for article (PubMed ID: 1007279)
21. BCG immunotherapy in previously treated malignant melanoma patients.
Mujagić H; Kolarić K; Malenica B; Nola P
Biomedicine; 1979 Jun; 30(2):95-102. PubMed ID: 476270
[TBL] [Abstract][Full Text] [Related]
22. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene.
Cohen MH; Jessup JM; Felix EL; Weese JL; Herberman RB
Cancer; 1978 Jun; 41(6):2456-63. PubMed ID: 657108
[TBL] [Abstract][Full Text] [Related]
23. Immunological monitoring of melanoma patients on BCG immunotherapy. I. Enzyme-linked immunosorbent assay of human sera after BCG-treatment.
Kovatchev D; Kolushky V; Engibarov A
Neoplasma; 1984; 31(4):453-8. PubMed ID: 6472516
[TBL] [Abstract][Full Text] [Related]
24. [Basis for a specific-active immunotherapy in malignant melanoma].
Mutzner PA; Stuhlmiller GM; Seigler HF; Stumpf WE; Sar M
Schweiz Med Wochenschr; 1981 Sep; 111(36):1322-5. PubMed ID: 7302537
[TBL] [Abstract][Full Text] [Related]
25. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line.
Waanders GA; Rimoldi D; Liénard D; Carrel S; Lejeune F; Dietrich PY; Cerottini JC; Romero P
Clin Cancer Res; 1997 May; 3(5):685-96. PubMed ID: 9815737
[TBL] [Abstract][Full Text] [Related]
26. Nonspecific antigen reactions.
Klein E; Rosner D; Holtermann OA; Stoll HL; Song SY
Natl Cancer Inst Monogr; 1976 Nov; 44():87-97. PubMed ID: 799764
[TBL] [Abstract][Full Text] [Related]
27. Tumor-directed immune reactivity and immunotherapy in malignant melanoma. Current status.
Mavligit G; Gutterman JU; McBride C; Hersh EM
Prog Exp Tumor Res; 1974; 19():222-52. PubMed ID: 4612607
[No Abstract] [Full Text] [Related]
28. A technique for intensifying BCG sensitivity.
Parmett SR; Klein E
J Med; 1975; 6(3-4):213-6. PubMed ID: 1104733
[TBL] [Abstract][Full Text] [Related]
29. [Local immunotherapy. Alternative therapy for malignant cutaneous lesions (demonstration on 30 patients with malignant melanoma) (author's transl)].
Kokoschka EM; Micksche M
Wien Klin Wochenschr; 1979 Mar; 91(5):150-4. PubMed ID: 425533
[TBL] [Abstract][Full Text] [Related]
30. Effects of BCG and Corynebacterium parvum on immune reactivity in melanoma patients.
Thatcher N; Crowther D
Dev Biol Stand; 1977 Apr 13-15; 38():449-53. PubMed ID: 608536
[TBL] [Abstract][Full Text] [Related]
31. [Development in the immunotherapy of malignant melanoma].
Tritsch H
Hautarzt; 1976 Jan; 27(1):1-7. PubMed ID: 767300
[TBL] [Abstract][Full Text] [Related]
32. Induction of peptide-specific immune response in patients with primary malignant melanoma of the esophagus after immunotherapy using dendritic cells pulsed with MAGE peptides.
Ueda Y; Shimizu K; Itoh T; Fuji N; Naito K; Shiozaki A; Yamamoto Y; Shimizu T; Iwamoto A; Tamai H; Yamagishi H
Jpn J Clin Oncol; 2007 Feb; 37(2):140-5. PubMed ID: 17255158
[TBL] [Abstract][Full Text] [Related]
33. Immunologic evaluation of patients with cancer by delayed hypersensitivity reactions.
Burdick JF; Wells SA; Herberman RB
Surg Gynecol Obstet; 1975 Nov; 141(5):779-94. PubMed ID: 128144
[TBL] [Abstract][Full Text] [Related]
34. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.
Wang F; Bade E; Kuniyoshi C; Spears L; Jeffery G; Marty V; Groshen S; Weber J
Clin Cancer Res; 1999 Oct; 5(10):2756-65. PubMed ID: 10537339
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: five-year results of a prospective randomized study.
Galligioni E; Quaia M; Merlo A; Carbone A; Spada A; Favaro D; Santarosa M; Sacco C; Talamini R
Cancer; 1996 Jun; 77(12):2560-6. PubMed ID: 8640706
[TBL] [Abstract][Full Text] [Related]
36. [Immunology and therapy of malignant melanoma (author's transl)].
Kokoschka EM; Micksche M
Wien Klin Wochenschr; 1977 Sep; 89(18):612-22. PubMed ID: 906525
[TBL] [Abstract][Full Text] [Related]
37. BCG in cancer therapy: theoretical bases of immunotherapy.
Dodd MJ
Am J Nurs; 1979 Feb; 79(2):310-4. PubMed ID: 311587
[No Abstract] [Full Text] [Related]
38. Purification of soluble human melanoma-associated antigens.
Roth JA; Slocum HK; Pellegrino MA; Holmes EC; Reisfeld RA
Cancer Res; 1976 Jul; 36(7 PT 1):2360-4. PubMed ID: 776393
[TBL] [Abstract][Full Text] [Related]
39. Demonstration of lymphocyte blastogenesis--inhibiting factors in sera of melanoma patients.
Rangel DM; Golub SH; Morton DL
Surgery; 1977 Aug; 82(2):224-32. PubMed ID: 877866
[TBL] [Abstract][Full Text] [Related]
40. Some aspects of cell-mediated hypersensitivity in patients with melanoma.
Moszkowska G; Jassem J; Kondrat W; Kopacz A; Goszczyńska E
Arch Immunol Ther Exp (Warsz); 1980; 28(4):655-60. PubMed ID: 6970028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
